On May 20th, Another Historic “Reserve Split” Will Take Place In The Markethttps://keystoneinvestor.com/club Anyone know anything about this ”historic reserve split” to happen on May 20th? URGENT WARNING TO ALL INVESTORS: On May 20th, Another Historic “Reserve Split” Will Take Place In The Market, Triggering A Tsunami Sized Wave Of Low-Risk Opportunity For Ordinary Men To Turn $1 Into $121 And Lock In Their Retirement For Good […]
Articles
- Most Relevant
- Most Recent
[ed. note: This is an introductory piece from longtime reader Peter Tilton, who has proposed writing a regular column for Stock Gumshoe readers about psychiatry. Not an investing topic (though the behavior of many of us in the markets may well be something that’s in need of a diagnosis), but we thought you might find […]
Streetsifter strikes again — he sent in this solution for an email that just started circulating, and he sent it in before I had even gotten around to reading the email. He even wrote it up nicely, so most of what follows is just a minor edit of his words (I agree he’s clearly got […]
The idea that we’re finally going to enter an era of just and profitable growth in Africa (or at least, sustainable growth) has been around for a long time, and it’s been wrong for a long time, as Africa has arguably been subject to more exploitation, poverty, and human suffering than your average continent over […]
How could I resist this tease? I’m the guy, after all, who needs to stir his little grey cells to recall the name of that beautiful shrub growing at the northeast corner of our house. Eureka, I’ve got it! – it’s called viburnum. I’ve always attributed my lapses in memory to the […]
[ed. note: Michael Jorrin, who I like to call “Doc Gumshoe” (he’s a longtime medical writer, not a doctor) writes about health and medicine topics for us from time to time. His words and thoughts are his own.] Let me begin with a disclaimer: I am not skinny, but neither am I fat. This chapter […]
The idea that we’re finally going to enter an era of just and profitable growth in Africa (or at least, sustainable growth) has been around for a long time, and it’s been wrong for a long time, as Africa has arguably been subject to more exploitation, poverty, and human suffering than your average continent over […]
Welcome back, volatility! I’ve got the remainder of my Annual Review to share with you in a separate post that will be released later on, but thought I’d get my big picture thinking out of the way for you first… including a brief update about the few portfolio moves that I made today as we […]
I believe that Harry Dent is bang-on with his Wave Pattern and demographic investment strategies although I doubt his forecasting abilities (particularly in relation to precious metals) purely because the world is in totally uncharted territory financially. After reading a few of his books I subscribed to Dent Research Boom & Bust simply for the […]
Just recently I’ve taken a long position in Immupharma and am quite excited about the potential. One of the fellow members on a BB had posted a very well researched and balanced article that I would like to share. So, with courtesy of Sicilian_kan [cheers!]: ”(last updated on 26 April 2016: Disclaimer – no information […]
I’ve been asked a few questions about the gold stocks in my portfolio, so I thought I’d run through a few of them today and provide whatever updated opinion and assessment I can for you — including a few portfolio adjustments I’ve just made. And, as an added bonus, I’m adding one new gold stock […]
That’s the way this teaser begins: “Government Ordinance 458 Guarantees Your Profits on the New “General Electric” of China” This is an ad not for a subscription, but for a special report from Michael Lombardi (who writes the free newsletter Profit Confidential) — the special report costs $95. I don’t see these very often, probably […]
Doc Gumshoe is not in the habit of contradicting the conclusions, backed by research, that are stated in papers published by the Journal of the American Medical Association, commonly referred to as JAMA. JAMA is, after all, one of a handful of the most prestigious medical journals on the planet, along with the New […]
After Gumshoe made some coments about the yearly result spreadsheets, I took a look. STTYF shows a reviewed at 0.48, and a current value around $1.60 or so, thus showing a profit. I cannot find it mentioned prior to 2012, and it was never that low in 2012. Am I blind, or are the spreadsheets?
[ed. note: Michael Jorrin, who I dubbed “Doc Gumshoe” years ago, is a longtime medical writer (not a doctor) who writes for us a couple times a month about health issues, marketing, and trends. He does not typically focus on specific investment opportunities, but has agreed to our trading restrictions… as with all of our […]
Ok, this is definitely the “most requested” ad over the last 24 hours — I can’t tell you how many folks have asked your friendly neighborhood Gumshoe to look into “Living Metal,” but the list is getting loooong. And we are, of course, happy to oblige. The pitch is from Michael Robinson for his Radical […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his words and opinions are his own. You can find his bio and his past articles on his Stock Gumshoe page.] “The universe (which others call the Library) is composed of an indefinite and […]
This is the first ticker specific discussion…..if it works, there may be many others. The aim is to have a chronological knowledge diary. If your comment is about ANYTHING other than $ARTH…please DONT post it here. **Please note that this post has been closed to further comment. The discussion on ARTH has moved over to […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading restrictions, chooses his own topics, and his words and opinions are his own. All of his past articles and most recent comments are on his Stock Gumshoe page.] Ho ho ho! And Happy Christmas to all […]
We will no longer be publishing the commentary of Dr. KSS, who wrote about biotech stocks for the Irregulars for several years. Late last week, he decided to move on and resign from his work here. I imagine he will likely start his own publication of some sort in the future — all I know […]
In his tearjerker “Sisters of Mercy,” Leonard Cohen sings, I’ve been where you’re hanging and think I can see how you’re pinned. Although I am less inclined to bash the FDA than many, it has recently let modern medical practice place many patients in an undesirable situation. What if there was a very powerful drug, […]
[Ed. Note: Dr. KSS writes for the Irregulars about medicine and biotech stocks. He chooses his own topics, and his words and opinions are his own.] Careful analysis of Ebola sequences in infected Africans confirms this: the entire present Ebola outbreak emerged as a consequence of one boy in Meliandoua, in eastern Guinea, eating a […]
from morning news about new colon cancer dna test called cologuard by exact sciences mkt. cap $1.95B. Missed Oct. earnings, Down 1.3% premkt. Any information? What may be yours and Dr.Kss and Blind squirrels thoughts. signed an Avid follower. and of course many many thanks
I’ve got a few thoughts for you on some companies I follow and own, and a little follow-up on last week’s chatter about hedge funds, but first I thought you’d like a quick teaser solution for your Friday File fun… The pitch is for Stephen Petranek’s Breakthrough Technology Alert — there’s been some discussion recently […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. This article is third in a series on pain. You can see the first part here, and second part here. His words and opinions are his own, and he has agreed to our trading restrictions. Enjoy!] It’s the stuff of bucket lists: eating fugu […]
I have to warn you up front, after reading through this before sending it out to you I’m a little worried. You might think I’m a bit “off my meds” today — I didn’t have one coherent idea to share, so I ended up with a stream of consciousness that’s a jumble of ideas, ranting, […]
[Ed. Note: Dr. KSS writes about medical topics and biotech stocks for the Irregulars. He choses his own topics, and his words and opinions are his own. Part one of this series is here if you missed it. Enjoy!] “The heat was hot and the ground was dry but the air was full of sound. I’ve […]
[ed. note: Dr. KSS writes about biotech stocks for the Irregulars. He has agreed to our trading restrictions, but he chooses his own topics and his words and thoughts are his own] According to new SEC filings, Cellceutix President, co-founder and Chief Scientific Officer Krishna Menon has recently settled what should probably be regarded as […]
[Ed. Note: Dr. KSS writes about medical topics and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his thoughts and words are his own. Enjoy!] Here we are, solidly in the postmodern 21st century, “so late in the goddam day,” as one of novelist Martin Amis’s characters says, and what […]
Ok, this is definitely the “most requested” ad over the last 24 hours — I can’t tell you how many folks have asked your friendly neighborhood Gumshoe to look into “Living Metal,” but the list is getting loooong. And we are, of course, happy to oblige. The pitch is from Michael Robinson for his Radical […]
[Ed. Note: Dr. KSS writes about medical topics and biotech stocks for the Irregulars. He has agreed to our trading restrictions, and his thoughts and words are his own. Enjoy!] Any discussion of cholesterol immediately turns Brobdingnagian, such are the extremes in question. Statins, which lower LDL cholesterol, are bombastically the best-selling drugs of all […]
Famous families and historical fortunes fascinate investors — the idea that these families you know and (sometimes) worship created vast fortune because of one wily speculator way back in the family tree is almost irresistibly interesting. It gives us the feeling that any family can rise up and make a big bet on the way […]
[ed. note: Michael Jorrin, who I like to call “Doc Gumshoe” (he’s a longtime medical writer, not a doctor) writes about health and medicine topics for us from time to time. His words and thoughts are his own.] Let me begin with a disclaimer: I am not skinny, but neither am I fat. This chapter […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. He has agreed to our trading rules and he chooses his own topics. His words and opinions are his own. Enjoy!] In June 1962, women working in the dressmaking arm of a certain American textile factory were overcome with fear. Rumors began […]
[ed. note: Michael Jorrin, who I like to call “Doc Gumshoe” (he’s a longtime medical writer, not a doctor) writes about health and medicine topics for us from time to time. His words and thoughts are his own.] The word “placebo” is the first person singular, future tense, of the Latin verb “placere,” to please […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. His words and opinions are his own. Enjoy!] In the Saturday morning Looney Tunes many of us saw as children, one trope always stuck with me: that of the grand piano falling from way up high and crashing, splintering itself. There’s a […]
[Ed. Note: Jim Skelton, The Blind Squirrel, writes a monthly column for us about his experience as a Financial Advisor. His topics, thoughts and opinions are his own. Enjoy!] Greetings once again to the Gumshoe Nation! Your resident Blind Squirrel returning for June with what will be the last posting regarding the Dogs of the […]
[Ed. Note: Dr. KSS writes about medicine and biotech stocks for the Irregulars. His words and opinions are his own.] In A History of New York, Washington Irving opens chapter VIII thus: ”In which the author and reader…fall into a very grave and instructive discourse.” This may prove to be a more unleavened column than […]
The following article originally appeared on February 11, 2014 — several readers have asked about the “blue blood” pitch for this “cancer cure” (there’s a reason why we use quotes there) so we’re putting it on top of the page in case you’re curious. My opinion on this one is unchanged, I’m still pretty skeptical […]
What’s the commonest reason for admission to hospital of people 65 and over? Mull that question, as it provides context. Think of people you know. At least one probably has this condition. It’s not diabetes. It’s not heart attacks. And it is not infectious. But it kills and lots of people have it. Part II […]